Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Why now
Thesis: $1.05B convertible offering dilutes equity, signals capital need
Catalyst to watch: Pricing terms and use of proceeds
Main risk: Near-term share pressure from dilution
Why it matters
A $1.05B convertible offering dilutes equity and signals capital need, typically pressuring shares near term.
Details
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the...
Related assets & topics
Banco Santander · SANNasdaq Composite · ^IXICHealthcareSPDR Biotech ETF · XBISources
- prnewswire · 2026-09-16 20:30 UTC